Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Overexpression of anti-apoptotic Bcl-2 family proteins in tumors like prostate cancer leads to resistance to cell death.
• Restoring apoptosis mechanisms is a key therapeutic strategy for cancer treatment.
• Prostate-specific membrane antigen (PSMA) is a target on prostate cancer cells.

Purpose of the Study:

• To evaluate the efficacy of a recombinant immunotoxin (D7(VL-VH)-PE40) targeting PSMA in prostate cancer.
• To investigate the synergistic effect of combining the immunotoxin with the BH3 mimetic ABT-737.
• To assess the combined therapy's ability to induce apoptosis in prostate cancer cells.

Main Methods:

• Development of a recombinant immunotoxin D7(VL-VH)-PE40 targeting PSMA and utilizing Pseudomonas Exotoxin A (PE40).
• Testing the immunotoxin's binding and cytotoxicity against PSMA-expressing prostate cancer cells.
• Combination therapy with the immunotoxin and ABT-737 (a Bcl-2, Bcl-xl, Bcl-w inhibitor) assessed for apoptosis induction via Western blot analysis of PARP and Caspase-3 cleavage.

Main Results:

• The immunotoxin demonstrated high, specific binding and cytotoxicity against PSMA-positive prostate cancer cells.
• The immunotoxin directly inhibited Mcl-1 expression.
• Combining the immunotoxin with subtoxic ABT-737 concentrations resulted in additive or synergistic apoptosis induction.

Conclusions:

• The combination of D7(VL-VH)-PE40 immunotoxin and ABT-737 significantly enhances apoptosis in prostate cancer cells.
• This combination therapy represents a promising strategy for advanced prostate cancer treatment.
• The approach may improve therapeutic outcomes and mitigate adverse effects in prostate cancer patients.